{"product_id":"diabetes-drug-notes-isbn-9781119785002","title":"Diabetes Drug Notes","description":"\u003cb\u003eDIABETES DRUG NOTES\u003c\/b\u003e  \u003cp\u003eDiabetes is becoming more common in both older and younger generations and in keeping with this escalation in cases, there are an ever increasing number of drugs and drug classes that are suitable to treat hyperglycaemia. In a unique blend of diabetes practice, clinical pharmacology, and cardiovascular medicine, \u003ci\u003eDiabetes Drug Notes\u003c\/i\u003e describes the principles of clinical pharmacology with regards to diabetes prescribing. Each drug class for the treatment of diabetes is covered in detail, along with the effect on the cardiovascular and renal systems caused by each drug. Building upon the success of their “Drug Notes” series for \u003ci\u003ePractical Diabetes\u003c\/i\u003e and their “Drugs for Diabetes” series in the \u003ci\u003eBritish Journal of Cardiology,\u003c\/i\u003e the team of experts focuses on the glycaemic management of type 1 and type 2 diabetes, with other effects of antidiabetic drugs covered as well. \u003c\/p\u003e\u003cp\u003e\u003ci\u003eDiabetes Drug Notes \u003c\/i\u003ealso includes: \u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eComprehensive and up-to-date coverage of the drugs for the glycaemic management of patients with type 1 or type 2 diabetes\u003c\/li\u003e \u003cli\u003eExpert reflection on prescribing considerations for special groups, as well as common pitfalls in prescribing\u003c\/li\u003e \u003cli\u003eDetailed case histories to illustrate relevant information\u003c\/li\u003e \u003cli\u003eSummaries of recent guidelines related to diabetic intervention\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003e\u003ci\u003eDiabetes Drug Notes\u003c\/i\u003e is a user-friendly guide for a general diabetes medical, nursing, and pharmacology readership, as well as those who support them. \u003c\/p\u003e\u003cp\u003eForeword xx\u003c\/p\u003e \u003cp\u003ePreface xxi\u003c\/p\u003e \u003cp\u003eEditors and Contributors xxii\u003c\/p\u003e \u003cp\u003eIntroduction 1\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Clinical Pharmacology of Antidiabetic Drugs 2\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eAndrea Llano, Gerry McKay, and Ken Paterson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 2\u003c\/p\u003e \u003cp\u003eClinical Pharmacology 3\u003c\/p\u003e \u003cp\u003eDrug Metabolism and Elimination 6\u003c\/p\u003e \u003cp\u003eDrug Development and Clinical Trials 7\u003c\/p\u003e \u003cp\u003eDrug Licensing of Antidiabetic Drugs 12\u003c\/p\u003e \u003cp\u003eDevelopment and Licensing of Insulin 14\u003c\/p\u003e \u003cp\u003eDevelopment and Approval of Biosimilar Insulin 16\u003c\/p\u003e \u003cp\u003ePharmacovigilance 19\u003c\/p\u003e \u003cp\u003ePharmacoeconomics 21\u003c\/p\u003e \u003cp\u003eFuture Developments in Diabetes Clinical Pharmacology 26\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Metformin 30\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eJoseph Timmons and James Boyle\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 30\u003c\/p\u003e \u003cp\u003ePharmacology 32\u003c\/p\u003e \u003cp\u003eMechanism of Action 32\u003c\/p\u003e \u003cp\u003eGlycaemic Efficacy 36\u003c\/p\u003e \u003cp\u003eSafety and Side Effects 37\u003c\/p\u003e \u003cp\u003eMetformin in Type 1 Diabetes 45\u003c\/p\u003e \u003cp\u003ePlace of Metformin in Current and Future Practice 46\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Sulfonylureas and Meglitinides 49\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eJoseph Timmons and James Boyle\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 49\u003c\/p\u003e \u003cp\u003ePharmacology 51\u003c\/p\u003e \u003cp\u003eGlycaemic Efficacy 53\u003c\/p\u003e \u003cp\u003eSafety and Side Effects 55\u003c\/p\u003e \u003cp\u003eOutcome Trials 56\u003c\/p\u003e \u003cp\u003eMeglitinides 61\u003c\/p\u003e \u003cp\u003ePlace of Sulfonylureas and Meglitinides in Current and Future Practice 65\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 DPP-4 Inhibitors 67\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eSharon Mackin and Gemma Currie\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 67\u003c\/p\u003e \u003cp\u003ePharmacology 68\u003c\/p\u003e \u003cp\u003eGlycaemic Efficacy 75\u003c\/p\u003e \u003cp\u003eSafety and Side Effects 79\u003c\/p\u003e \u003cp\u003eOutcome Trials 82\u003c\/p\u003e \u003cp\u003eRenal Outcomes 89\u003c\/p\u003e \u003cp\u003eThe Place of DPP-4 Inhibitors in Current and Future Practice 91\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 SGLT2 Inhibitors 95\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eMiles Fisher, Andrea Llano, and Gerry McKay\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 96\u003c\/p\u003e \u003cp\u003ePharmacology 96\u003c\/p\u003e \u003cp\u003eGlycaemic Efficacy 100\u003c\/p\u003e \u003cp\u003eSide Effects and Safety 103\u003c\/p\u003e \u003cp\u003eOutcome Trials 105\u003c\/p\u003e \u003cp\u003eRenal Outcome Trials 110\u003c\/p\u003e \u003cp\u003eHeart Failure Outcome Trials 116\u003c\/p\u003e \u003cp\u003eSGLT2 Inhibitors in Type 1 Diabetes 119\u003c\/p\u003e \u003cp\u003eUse of SGLT2 Inhibitors in Other Diseases 123\u003c\/p\u003e \u003cp\u003eDare- 19 123\u003c\/p\u003e \u003cp\u003ePlace of SGLT2 Inhibitors in Current and Future Practice 124\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 GLP-1 Receptor Agonists 130\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eCatherine Russell and John Petrie\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 130\u003c\/p\u003e \u003cp\u003ePharmacology 131\u003c\/p\u003e \u003cp\u003eGlycaemic Efficacy and Effect on Weight 137\u003c\/p\u003e \u003cp\u003eSide Effects and Safety 142\u003c\/p\u003e \u003cp\u003eOutcome Trials 143\u003c\/p\u003e \u003cp\u003eUse of GLP-1 Receptor Agonists in Other Diseases 153\u003c\/p\u003e \u003cp\u003ePlace of GLP-1 Receptor Agonists in Current and Future Practice 155\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Animal and Human Insulins 161\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eKen Paterson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 161\u003c\/p\u003e \u003cp\u003eProduction and Pharmacokinetic Modifications 165\u003c\/p\u003e \u003cp\u003eHypoglycaemia and Human Insulin 170\u003c\/p\u003e \u003cp\u003eIntensified Insulin Therapy 173\u003c\/p\u003e \u003cp\u003ePlace of Human Insulin in Current and Future Therapy 176\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Short-acting Insulin Analogues 179\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eKate Hughes and Gerry McKay\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 179\u003c\/p\u003e \u003cp\u003eFactors Affecting Absorption and Metabolism of Short-acting Insulin 180\u003c\/p\u003e \u003cp\u003eManufacturing Insulin Analogues 180\u003c\/p\u003e \u003cp\u003eShort-acting Insulin Analogues 182\u003c\/p\u003e \u003cp\u003eSecond-generation Ultrafast-acting Insulin Analogues 186\u003c\/p\u003e \u003cp\u003eOther Attempts to Improve Insulin Absorption and Inhaled Insulin 189\u003c\/p\u003e \u003cp\u003ePlace of Short-acting Insulin Analogues in Current and Future Practice 190\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Long-acting Insulin Analogues 194\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eRobert Lindsay\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 195\u003c\/p\u003e \u003cp\u003eDevelopment of Long-acting Insulin Analogues 196\u003c\/p\u003e \u003cp\u003eLong-acting Insulin Analogues 197\u003c\/p\u003e \u003cp\u003eMeta-analysis of Glycaemic Efficacy of Long-acting Insulin Analogues 207\u003c\/p\u003e \u003cp\u003eSafety of Long-acting Insulin Analogues 209\u003c\/p\u003e \u003cp\u003eThe Place of Long-acting Insulin Analogues in Current and Future Practice 209\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Devices 214\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eDavid Carty\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 214\u003c\/p\u003e \u003cp\u003eInsulin Pens 215\u003c\/p\u003e \u003cp\u003eInsulin Pumps 215\u003c\/p\u003e \u003cp\u003eSelf-monitoring of Blood Glucose 218\u003c\/p\u003e \u003cp\u003eLinkage of Continuous Glucose Monitoring to Insulin Pumps 223\u003c\/p\u003e \u003cp\u003eGuidelines on the Use of Devices 225\u003c\/p\u003e \u003cp\u003ePlace of Devices in Current and Future Practice 227\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Acarbose and Alpha Glucosidase Inhibitors 229\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eMiles Fisher\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 229\u003c\/p\u003e \u003cp\u003ePharmacology 230\u003c\/p\u003e \u003cp\u003eGlycaemic Efficacy 231\u003c\/p\u003e \u003cp\u003ePlace of Alpha Glucosidase Inhibitors in Current and Future Practice 237\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Glitazones and Glitazars 239\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eMiles Fisher\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 239\u003c\/p\u003e \u003cp\u003ePharmacology 240\u003c\/p\u003e \u003cp\u003eGlycaemic Efficacy 241\u003c\/p\u003e \u003cp\u003eSafety and Side Effects 242\u003c\/p\u003e \u003cp\u003eGlitazars 252\u003c\/p\u003e \u003cp\u003ePlace of Glitazones and in Current and Future Practice 253\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Other Antidiabetic Drugs 257\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eMaroria Oroko, Andrea Llano, and Miles Fisher\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 257\u003c\/p\u003e \u003cp\u003ePramlintide 258\u003c\/p\u003e \u003cp\u003eColesevelam 260\u003c\/p\u003e \u003cp\u003eBromocriptine 262\u003c\/p\u003e \u003cp\u003eHydroxychloroquine 264\u003c\/p\u003e \u003cp\u003eAntiobesity Drugs 265\u003c\/p\u003e \u003cp\u003ePlace of Other Drugs in Current and Future Practice 270\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Future Antidiabetic Drugs 274\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eEmma Johns and Miles Fisher\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 274\u003c\/p\u003e \u003cp\u003eDual and Triple Agonists 275\u003c\/p\u003e \u003cp\u003eImeglimin 288\u003c\/p\u003e \u003cp\u003ePlace of New Antidiabetic Drugs in Future Practice 291\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Guidelines on Antidiabetic Drugs 294\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eMiles Fisher and Russell Drummond\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 295\u003c\/p\u003e \u003cp\u003eGuidelines on the Use of Antidiabetic Drugs in Type 2 Diabetes 298\u003c\/p\u003e \u003cp\u003eGuidelines on the Management of Type 1 Diabetes 308\u003c\/p\u003e \u003cp\u003eSpecial Patient Groups 311\u003c\/p\u003e \u003cp\u003ePlace of Guidelines in Current and Future Practice 318\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 Prescribing Antidiabetic Drugs 322\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eAndrea Llano, Gerry McKay, Frances McManus, Catriona McClements, Joyce McKenzie, and Deborah Morrison\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 322\u003c\/p\u003e \u003cp\u003eTherapeutic Inertia 323\u003c\/p\u003e \u003cp\u003ePolypharmacy 326\u003c\/p\u003e \u003cp\u003eNonadherence 329\u003c\/p\u003e \u003cp\u003eThe Patient with Problematic Hypoglycaemia 330\u003c\/p\u003e \u003cp\u003ePrescribing in Renal Impairment 333\u003c\/p\u003e \u003cp\u003ePrescribing in Liver Disease 337\u003c\/p\u003e \u003cp\u003ePrescribing in Cardiovascular Disease 340\u003c\/p\u003e \u003cp\u003ePrescribing in Pregnancy 347\u003c\/p\u003e \u003cp\u003ePrescribing in the Young 348\u003c\/p\u003e \u003cp\u003ePrescribing in the Elderly 349\u003c\/p\u003e \u003cp\u003eThe Patient with Type 1 Diabetes: a Therapeutic Journey (an Illustrative Case) 350\u003c\/p\u003e \u003cp\u003eThe Patient with Type 2 Diabetes: a Therapeutic Journey (an Illustrative Case) 351\u003c\/p\u003e \u003cp\u003eFuture Developments in Prescribing in Diabetes 353\u003c\/p\u003e \u003cp\u003eAppendix 357\u003c\/p\u003e \u003cp\u003eIndex 359\u003c\/p\u003e \u003cp\u003e\u003cb\u003eProf. Miles Fisher\u003c\/b\u003e is a former Consultant Physician, Department of Diabetes, Endocrinology and Clinical Pharmacology, Glasgow Royal Infirmary, and an Honorary Professor at the University of Glasgow, UK.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eProf. Gerard A. McKay\u003c\/b\u003e is a Consultant Physician, Department of Diabetes, Endocrinology and Clinical Pharmacology, Glasgow Royal Infirmary, an Honorary Clinical Associate Professor, University of Glasgow, as well as a Visiting Professor at the University of Strathclyde, UK.  \u003c\/p\u003e\u003cp\u003e\u003cb\u003eDr Andrea Llano\u003c\/b\u003e is a Consultant Physician, Department of Diabetes, Endocrinology and Clinical Pharmacology, Glasgow Royal Infirmary, and an Honorary Clinical Lecturer, University of Glasgow, UK.  \u003c\/p\u003e\u003cp\u003eDiabetes is becoming more common in both older and younger generations and in keeping with this escalation in cases, there are an ever increasing number of drugs and drug classes that are suitable to treat hyperglycaemia. In a unique blend of diabetes practice, clinical pharmacology, and cardiovascular medicine, \u003ci\u003eDiabetes Drug Notes\u003c\/i\u003e describes the principles of clinical pharmacology with regards to diabetes prescribing. Each drug class for the treatment of diabetes is covered in detail, along with the effect on the cardiovascular and renal systems caused by each drug. Building upon the success of their “Drug Notes” series for \u003ci\u003ePractical Diabetes\u003c\/i\u003e and their “Drugs for Diabetes” series in the \u003ci\u003eBritish Journal of Cardiology,\u003c\/i\u003e the team of experts focuses on the glycaemic management of type 1 and type 2 diabetes, with other effects of antidiabetic drugs covered as well.\u003c\/p\u003e \u003cp\u003e\u003ci\u003eDiabetes Drug Notes \u003c\/i\u003ealso includes: \u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eComprehensive and up-to-date coverage of the drugs for the glycaemic management of patients with type 1 or type 2 diabetes\u003c\/li\u003e \u003cli\u003eExpert reflection on prescribing considerations for special groups, as well as common pitfalls in prescribing\u003c\/li\u003e \u003cli\u003eDetailed case histories to illustrate relevant information\u003c\/li\u003e \u003cli\u003eSummaries of recent guidelines related to diabetic intervention\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003e\u003ci\u003eDiabetes Drug Notes\u003c\/i\u003e is a user-friendly guide for a general diabetes medical, nursing, and pharmacology readership, as well as those who support them.\u003c\/p\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47989056667877,"sku":"NP9781119785002","price":90.0,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781119785002.jpg?v=1761782614","url":"https:\/\/k12savings.com\/es\/products\/diabetes-drug-notes-isbn-9781119785002","provider":"K12savings","version":"1.0","type":"link"}